SCHEMBL310670

SCHEMBL310670

CC(NC(C#N)CCC(F)(F)F)c1ccccc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 1/20 0.41
CTSL P07711 7/20 0.40
CYP3A4 P08684 2/20 0.39
CHRM2 P08172 1/20 0.39
HTR1A P08908 1/20 0.39
ADRA2A P08913 1/20 0.39
ADORA3 P0DMS8 1/20 0.39
CHRM1 P11229 1/20 0.39
SMPD1 P17405 1/20 0.39
DRD1 P21728 1/20 0.39
TBXA2R P21731 1/20 0.39
SLC6A2 P23975 1/20 0.39
SLC6A4 P31645 1/20 0.39
ADRA1A P35348 1/20 0.39
OPRM1 P35372 1/20 0.39
DRD3 P35462 1/20 0.39
CASR P41180 1/20 0.39
HTR2B P41595 1/20 0.39
SLC6A3 Q01959 1/20 0.39
KCNH2 Q12809 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12810249 1.00 SIGMAR1 (0.41) SIGMAR1CTSLCYP3A4CHRM2HTR1A
SCHEMBL10069163 1.00 SIGMAR1 (0.41) SIGMAR1CTSLCYP3A4CHRM2HTR1A
SCHEMBL8419059 0.86 SIGMAR1 (0.42) SIGMAR1CTSLCYP3A4CHRM2HTR1A
SCHEMBL7900384 0.82 CTSL (0.39) CTSLCTSSCTSK
SCHEMBL24298107 0.79 SIGMAR1 (0.40) SIGMAR1CTSLCHRM2HTR1AADRA2A
SCHEMBL26829207 0.79 SIGMAR1 (0.40) SIGMAR1CTSLCHRM2HTR1AADRA2A
SCHEMBL24298108 0.79 SIGMAR1 (0.40) SIGMAR1CTSLCHRM2HTR1AADRA2A
SCHEMBL25767154 0.79 SIGMAR1 (0.47) SIGMAR1CYP3A4CHRM2HTR1AADRA2A
SCHEMBL24298254 0.76 CTSL (0.39) SIGMAR1CTSLMEN1KMT2ACTSS
SCHEMBL26127160 0.76 CTSL (0.39) SIGMAR1CTSLMEN1KMT2ACTSS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2408757-B1 A NOVEL ALPHA-(N-SULFONAMIDO) ACETAMIDE COMPOUND INCORPORATING DEUTERIUM AS INHIBITOR OF BETA AMYLOID PEPTIDE PRODUCTION BRISTOL MYERS SQUIBB CO (US) 2014-06-25 EP disclosed
EP-2408450-B1 ALPHA-(N-SULFONAMIDO)ACETAMIDE COMPOUND AS AN INHIBITOR OF BETA AMYLOID PEPTIDE PRODUCTION BRISTOL MYERS SQUIBB CO (US) 2013-03-13 EP disclosed
US-8350084-B2 Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production BRISTOL-MYERS SQUIBB COMPANY (US) 2013-01-08 US disclosed
EP-2471769-A1 Process for preparing a benzonitrile derivative Bristol-Myers Squibb Company (US) 2012-07-04 EP disclosed
EP-2295417-B1 Novel intermediates useful for preparing alpha-(n-sulfonamido)acetamide compound BRISTOL MYERS SQUIBB CO (US) 2012-07-04 EP disclosed
US-20120088925-A1 Novel Alpha-(N-Sulfonamido)Acetamide Compound as an Inhibitor of Beta Amyloid Peptide Production BRISTOL-MYERS SQUIBB COMPANY 2012-04-12 US disclosed
EP-2408757-A1 NOVEL ALPHA-(N-SULFONAMIDO)ACETAMIDE COMPOUNDS INCORPORATING DEUTERIUM AS INHIBITORS OF BETA AMYLOID PEPTIDE PRODUCTION A NOVEL ALPHA-(N-SULFONAMIDO) ACETAMIDE COMPOUND INCORPORATING DEUTERIUM AS INHIBITOR OF BETA AMYLOID PEPTIDE PRODUCTION Bristol-Myers Squibb Company (US) 2012-01-25 EP disclosed
EP-2408450-A1 A NOVEL ALPHA-(N-SULFONAMIDO)ACETAMIDE COMPOUND AS AN INHIBITOR OF BETA AMYLOID PEPTIDE PRODUCTION Bristol-Myers Squibb Company (US) 2012-01-25 EP disclosed
US-8093276-B2 Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production BRISTOL-MYERS SQUIBB COMPANY (US) 2012-01-10 US disclosed
US-8084477-B2 Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production BRISTOL-MYERS SQUIBB COMPANY (US) 2011-12-27 US disclosed
US-8044077-B2 Alpha-(N-sulfonamido)acetamide compounds incorporating deuterium as inhibitors of beta amyloid peptide production BRISTOL-MYERS SQUIBB COMPANY (US) 2011-10-25 US disclosed
US-20110071199-A1 Thiophenyl Sulfonamides for the Treatment of Alzheimer's Disease BRISTOL-MYERS SQUIBB COMPANY 2011-03-24 US disclosed
EP-2295417-A1 Novel intermediates useful for preparing alpha-(n-sulfonamido)acetamide compound Bristol-Myers Squibb Company (US) 2011-03-16 EP disclosed
EP-2205575-B1 A NOVEL ALPHA-(N-SULFONAMIDO)ACETAMIDE COMPOUND AS AN INHIBITOR OF BETA AMYLOID PEPTIDE PRODUCTION BRISTOL MYERS SQUIBB CO (US) 2011-03-16 EP disclosed
US-20100240719-A1 NOVEL ALPHA-(N-SULFONAMIDO)ACETAMIDE COMPOUNDS INCORPORATING DEUTERIUM AS INHIBITORS OF BETA AMYLOID PEPTIDE PRODUCTION BRISTOL-MYERS SQUIBB COMPANY 2010-09-23 US disclosed
WO-2010107435-A1 A NOVEL ALPHA-(N-SULFONAMIDO)ACETAMIDE COMPOUND AS AN INHIBITOR OF BETA AMYLOID PEPTIDE PRODUCTION BRISTOL-MYERS SQUIBB COMPANY (US) 2010-09-23 WO disclosed
WO-2010107984-A1 NOVEL ALPHA-(N-SULFONAMIDO)ACETAMIDE COMPOUNDS INCORPORATING DEUTERIUM AS INHIBITORS OF BETA AMYLOID PEPTIDE PRODUCTION A NOVEL ALPHA-(N-SULFONAMIDO) ACETAMIDE COMPOUND INCORPORATING DEUTERIUM AS INHIBITOR OF BETA AMYLOID PEPTIDE PRODUCTION BRISTOL-MYERS SQUIBB COMPANY (US) 2010-09-23 WO disclosed
US-20090227642-A1 NOVEL ALPHA-(N-SULFONAMIDO)ACETAMIDE COMPOUND AS AN INHIBITOR OF BETA AMYLOID PEPTIDE PRODUCTION BRISTOL-MYERS SQUIBB COMPANY 2009-09-10 US disclosed
US-20090111858-A1 Novel Alpha-(N-Sulfonamido)Acetamide Compound as an Inhibitor of Beta Amyloid Peptide Production BRISTOL-MYERS SQUIBB COMPANY 2009-04-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090111858-A1 Novel Alpha-(N-Sulfonamido)Acetamide Compound as an Inhibitor of Beta Amyloid Peptide Production APP, BACE1, IAPP SIGMAR1 2290/4885CTSL 1283/4885CYP3A4 4099/4885
US-20100240719-A1 NOVEL ALPHA-(N-SULFONAMIDO)ACETAMIDE COMPOUNDS INCORPORATING DEUTERIUM AS INHIBITORS OF BETA AMYLOID PEPTIDE PRODUCTION APP, BACE1, PSEN1 SIGMAR1 2482/4885CTSL 388/4885CYP3A4 4181/4885
US-20120088925-A1 Novel Alpha-(N-Sulfonamido)Acetamide Compound as an Inhibitor of Beta Amyloid Peptide Production APP, BACE1, IAPP SIGMAR1 2290/4885CTSL 1283/4885CYP3A4 4099/4885
US-20090227642-A1 NOVEL ALPHA-(N-SULFONAMIDO)ACETAMIDE COMPOUND AS AN INHIBITOR OF BETA AMYLOID PEPTIDE PRODUCTION APP, BACE1, APBA1 SIGMAR1 2559/4885CTSL 214/4885CYP3A4 4590/4885
US-20110071199-A1 Thiophenyl Sulfonamides for the Treatment of Alzheimer's Disease APP, PSEN1, PSEN2 SIGMAR1 1355/4885CTSL 1591/4885CYP3A4 3440/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.